Abstract Itch is a unique sensation associated with the scratch reflex. Although the scratch reflex plays a protective role in daily life by removing irritants, chronic itch remains a clinical challenge. Despite urgent clinical need, itch has received relatively little research attention and its mechanisms have remained poorly understood until recently. The goal of the present review is to summarize our current understanding of the mechanisms of acute as well as chronic itch and classifications of the primary itch populations in relationship to transient receptor potential (Trp) channels, which play pivotal roles in multiple somatosensations. The convergent involvement of Trp channels in diverse itch signaling pathways suggests that Trp channels may serve as promising targets for chronic itch treatments.
Introduction
Itch, also known as pruritus, is defined as an "unpleasant sensation that elicits the desire or reflex to scratch" [1] and can be distinguished as acute and chronic forms with the latter lasting more than 6 weeks [2] . Itch can be caused by various stimuli including those that are mechanical, electrical, and chemical, with exogenous and endogenous chemical stimuli ranging from amines, proteases, neuropeptides to inflammation mediators, and certain drugs (see Table 1 ) [3] . Acute itch, such as that caused by a mosquito bite, is commonly experienced in daily life and has a protective role as to remove irritants and avoid future insults. The mechanical pain generated by scratching can usually suppress acute itch. However, chronic itch conditions commonly accompanied by co-morbidities, such as depression and sleep disorders, can be debilitating and remain as unmet clinical needs. Chronic itch conditions are generally divided into four categories: dermatological, systemic, neurological, and psychogenic. Dermatological itch comes from skin conditions such as atopic dermatitis, psoriasis, and urticaria. Systemic itch can be caused by pathology of other organs, for example, liver cholestasis and kidney dialysis. Neurological itch is caused by direct damage to the nervous system either peripherally or centrally. Finally, psychogenic itch is associated with psychological and psychiatric disorders.
Itch sensation is initiated in the skin by peripheral afferents of primary sensory neurons, with cell bodies located in dorsal root ganglia (DRG) and trigeminal ganglia, then transmitted to the spinal dorsal horn and then further to the brain. Itch fibers are small unmyelinated C fibers and lightly myelinated Aδ fibers with slow conduction velocities and relatively small cell bodies, responding not only to itch but also to pain and other somatosensory stimuli.
Itch used to be regarded as a sub-modality of pain because of their similarities. The related theory is called intensity theory, stating that weak and strong activation of the same group of neurons generates itch and pain sensations, respectively [4] [5] [6] . Another competing theory is called labeled line theory, which, in contrast, proposes mutually exclusive populations for the detection of itch and pain [7] . It is clear now that itch is a distinct sensation from pain. Loss of the gastrin releasing peptide receptor (Grpr) population in the spinal cord resulted in a profound defect of itch behaviors, but pain responses remained intact unequivocally demonstrating the existence of separable itch and pain pathways [8] . However, periphery itch neurons are exclusively polymodal. They respond to painful stimuli such as capsaicin or mustard oil in addition to itchy stimuli [9] [10] [11] . The coding puzzle of itch and pain is better explained by selectivity theory. When the itch population is selectively activated, an itchy sensation is generated, regardless of the stimuli. In contrast, when an algogen activates a larger population, including both pain and itch-sensing neurons strong enough, itch is occluded by inhibition from pain neurons, just as scratching-induced pain inhibits itch and therefore, only pain sensation is perceived. Theoretically, itch and pain can be perceived at the same time when the amount of pain is not enough to mask itch. Although being two separate sensations, itch and pain share common downstream pathways. Recent evidence suggests transient receptor potential (Trp) channels play major roles in both itch and pain sensations.
Trp channels are a large family of six trans-membrane cation channels first identified in Drosophila to be mediator of photo-transduction. There are 28 identified Trp family members in mice and 27 in humans falling into six subgroups based on sequence homology (TrpC, TrpV, TrpM, TrpA, TrpP, and TrpML). Trp channels have been shown to play critical roles in various sensory functions including vision, olfaction, thermosensation, taste, mechanosensation, and pain [12] [13] [14] . Itch is newly added to the list based on recent research and is thus the focus of this review.
Trp channels and GPCRs in itch
With the booming of itch research in recent years, a common theme of itch transduction has emerged: pruritogens sensed by G protein-coupled receptors (GPCRs) with Trp channels downstream (see Fig. 1 ). G protein-coupled receptors are seven trans-membrane receptors capable of sensing various extracellular stimuli and triggering signaling inside cells. Ligand 
Histamine receptors
The most studied pruritogen is histamine, which serves as a classical example. Histamine can produce itch associated with flare and wheal in human skin [16] . All four histamine receptors, from H1R to H4R are G protein-coupled receptors. The H1R is presumed to be responsible for histamine-induced itch [17, 18] . TrpV1 is reported to be downstream as implicated by the observation that TrpV1 knockout reduced most histamineinduced itch [19] . Consistently, most histamine-sensitive small-diameter DRG neurons respond to capsaicin while only about 40 % of them respond to mustard oil, a TrpA1 agonist [9, 20] . TrpV1 also plays a pivotal role in the detection of noxious heat, pain, and the regulation of body temperature. TrpV1 can be activated by a wide variety of exogenous and endogenous stimuli including noxious heat (higher than 43°C), low pH, capsaicin, and endocannabinoid anandamide. Both the PLCβ/PKC pathway and the PLA2/lipoxygenase (LO) pathway have been proposed to link the Gq-coupled histamine receptor and TrpV1 (summarized in Fig. 1a ) [21] [22] [23] . However TrpV1 might not be the only Trp channel in histaminergic itch. In TrpV1-deficient mice, neither neuronal calcium response or behavioral scratching was completely eliminated and at the mean time, some histamine-responsive neurons failed to respond to capsaicin [19, 22, 24] . The critical role of H4R in histamine itch has also recently been recognized [25, 26] . Knockout of H4R greatly reduced histamineinduced itch and moreover, H1R/H4R double knockout or H4R knockout with H1R antagonist completely abolished the itch response, begging the question whether there are other Trp channels also involved in histaminergic itch, potentially downstream of H4R. However, detection of functional H4R expression in related brain regions raises the question of whether H4R mediates itch in the central nervous system. Tissue-specific knockout of H4R is best suited to clarify the role of H4R.
Other classic pruritogens like bradykinin, substance P, compound 48/80, PGE2, and platelet activating factor (PAF) can induce histamine release from mast cells, basophils, and others thus mediating itch largely in histamine-dependent way [27] [28] [29] [30] . Although there is report showing that high-dose bradykinin-elicited itch is not blocked by anti-histamine, bradykinin itch is largely histamine dependent [31] . Bradykinin works through the G protein-coupled B2 receptor (B2R) and 
Mas-related G protein-coupled receptors
Mas-related G protein-coupled receptors (Mrgprs) is a class of novel histamine-independent itch receptors with more than 50 members in mice [38, 39] . MrgprA3 is the receptor for the anti-malarial drug chloroquine, which causes severe antihistamine resistant itch as a side effect and scratching in mice. Bovine adrenal medulla (BAM) 22, an endogenous opioid peptide produced from proenkephalin gene and especially its cleaved product BAM 8-22 can potently activate MrgprC11 and induce itch in both humans and mice [9, 40] . BAM 8-22 generates histamine-independent itch not accompanied by flare and wheal when delivered to human skin. Both MrgprA3 and MrgprC11 are coupled to TrpA1 and are expressed in a small subset of largely overlap small-diameter DRG population (about 5-8 %) which also express histamine receptors as well as TrpV1 [10, 41] . TrpA1 knockout greatly reduced scratching produced by both chloroquine and BAM. TrpA1 is the only member of the TrpA subgroup and a key player in pain and inflammation. TrpA1 can be activated by various reactive compounds such as mustard oil, cinnamaldehyde, formalin, and hydrogen peroxide. Surprisingly, both G q/11 -coupled receptors in the largely overlapping population exhibit distinct signaling mechanisms. MrgprA3 is Gβγ-dependent but not coupled to phospholipase C (PLC) while MrgprC11 signaling requires PLC but not Gβγ (see Fig. 1b) .
MrgprD, another member from the family, is a receptor for β-alanine, a muscle-building supplement with non-histamine itch as side effect [42] . β-alanine feeding and intradermal delivery-evoked itch are MrgprD-dependent. Interestingly MrprD defines a unique itch population of DRGs not responding to either histamine or chloroquine. The downstream signaling mechanisms of MrgprD and involvement of Trp channels remains elusive.
Serotonin receptors
Serotonin (5-HT) iontophoresis in human skin induces itch with wheal and flare; however, only flare and itch (but not wheal) are anti-histamine-resistant, suggesting serotonin itch is histamine-independent [31, 43] 
Endothelin receptors
Endothelin is a vessel-constricting peptide primarily secreted by endothelial cells. In human skin, endothelin triggers itch with wheal and flare, which is not accompan i e d b y i n c r e a s e d h i s t a m i n e [6 2 ] . E n d o t h e l i n iontophoresis-induced itch in humans was only partially blocked by an H1R antagonist, indicating the participation of non-histamine mechanisms. There are three endothelin isoforms, ET-1, ET-2, and ET-3. The ET-1 isoform, commonly used in itch studies, increases during chronic itch diseases [63] . The ETa receptor antagonist suppresses ET-1-induced itch while the ETb receptor antagonist increases ET-1-induced itch [64, 65] . TrpA1, but not TrpV1, is critically involved as shown in a recent report by Kido-Nakahara et al. that only TrpA1 knockout abolished the ET-1 itch response [19, 63] . However, it remains controversial whether ET-1 works directly on DRGs or through indirect mechanisms. Endothelin receptors also express in non-neuronal cells. ET-1 elicited no or very weak calcium responses on DRGs and was not significantly affected by TrpA1 deficiency [63, 66] . KidoNakahara et al. also identified endothelin-converting enzyme 1 (ECE1), a neuronal peptidase mediating endothelin receptor recycling as a key modulator of ET-1 itch. Blocking ECE1 significantly boosted ET-1-induced scratching.
In addition, a recent study suggests that endothelin is responsible for aspartic protease cathepsin E-induced itch, as cathepsin E elevated the expression of endothelin and an ETa antagonist blocked the associated itch response [67] .
Protease-activated receptors
Protease-activated receptors (PARs) are a family of G proteincoupled receptors (PAR1 to PAR4) named after their ligands. PARs are distinguished from other GPCRs by their activation mechanism. The proteolytic cleave of the extracellular N terminus exposes the tethered ligand to activate the receptor itself [68] . The expression of proteases are elevated in multiple itchrelated diseases and cowhage, a tropical legume commonly used in studies of histamine-independent itch contains the protease mucunain as its active component [69] . PARs, especially PAR2, can be activated by various endogenous and exogenous itch-related proteases, including serine protease trypsin, tryptase, and cysteine protease cathepsin S, mucunain [69] [70] [71] . Thus, PAR2 is proposed to mediate protease-induced itch. Accordingly, expression of PAR2 and its ligand tryptase increase in chronic itch conditions [72] [73] [74] [75] .
SLIGRL-NH2, the tethered ligand of PAR2, is commonly used as a receptor agonist to study protease itch in animals [76] . However, a recent study shows that SLIGRL-NH2-induced itch surprisingly remained unaffected in PAR2 mutant mice, while trypsin generated more scratch bouts. Instead, Mrgprs deletion, in particular that of MrgprC11, significantly reduced SLIGRL-NH2-mediated response. Consistent with this, a shorter peptide SLIGR, agonist of PAR2 but not of MrgprC11, induced only thermal hyperalgesia but not itch [77] . This study implicates MrgprC11 as a mediator of protease-induced itch, but raises the question of whether MrgprC11 needs the PAR2 tethered ligand to trans-activate. This question is now addressed by a new study. Reddy et al. demonstrate that cysteine proteases, including cathepsin S and papain, directly activate MrgprC11 via proteolytic cleavage of the N terminus. Cathepsin S-mediated itch was significantly reduced in Mrgpr-null mice, but not in PAR2 mutant mice [78] . Mutations of residuals critical for protease cleavage abolished cathepsin S and papain-induced calcium response in heterologous cells showing the involvement of proteolytic cleavage. Interestingly, activation of MrgprC11 by protease does not involve tethered or diffusible ligands as neither of them served as an agonist. When the N terminus of MrgprC11 is replaced by that from an unrelated GPCR β2-adrenergic receptor (β2AR) or a melanocortin-1 receptor (MC1R) also containing a cysteine protease cleavage site but cannot be activated by proteolysis, both cathepsin S and papain can surprisingly still trigger robust calcium increase in Hela cells expressing these hybrid receptors suggesting proteolysis of MrgprC11 N terminus results in direct conformation change that allows G protein signaling. Thus, MrgprC11 demonstrates a novel GPCR activation mechanism after proteolysis.
In contrast, serine protease, tryptase has recently been shown to generate itch through PAR2 [79] . It will be interesting to determine whether another cysteine protease mucunain, the active component of cowhage, generates itch through PAR2 or MrgprC11. Although the precise role of Trp channels in protease itch is not yet clear, evidence strongly indicates involvement of Trp channels. PAR2 sensitizes both TrpV1 and TrpA1 to induce hyperalgesia [80, 81] , but whether the same mechanism is utilized in itch remains unknown. MrgprC11 with another ligand BAM is coupled to TrpA1, making TrpA1 a likely downstream mediator of protease itch.
In addition to G protein-coupled receptors, a few other receptors can also mediate itch responses, including cytokine receptors and toll-like receptors (TLRs). Trp channels are commonly utilized in these scenarios as well.
Cytokine receptors and Trp channels
Cytokine receptors are typically single trans-membrane proteins with a conserved extracellular cytokine receptor homology domain. Cytokine binding can induce receptor multimerization to activate Janus kinases (JAKs). Activated JAKs phosphorylate both receptors and themselves to recruit signal transducers and activators of transcription (STATs) and adaptors that link receptors to downstream mediators. Phosphorylated STATs can also dimerize and translocate to the nucleus to function as transcription factors [82] .
TSLP receptor
Thymic stromal lymphopoietin (TSLP) is an epithelial cellderived cytokine that is critical for Th2 response-related diseases such as atopic dermatitis [83] . Atopic dermatitis, also commonly known as atopic eczema, is a skin inflammation condition characterized by itchy, swollen, and cracked skin. Intradermal application of TSLP can elicit itch but not pain in mice. TSLP over-expression in mouse skin resulted in atopic dermatitis like phenotypes, demonstrating that TSLP is capable of directly triggering allergic inflammation cascades [84] . TSLP signals through a heterodimer of TSLP receptor chain and IL7 receptor α chain [85] . Wilson et al. recently identified TSLP receptor expression in about 5-6 % of DRGs, suggesting that TSLP acts directly on DRG neurons to generate itch sensation (Fig. 1b) . Consistently, mice lacking T cells, B cells, or mast cells retained their normal TSLP-induced itch response. TSLP-evoked scratches were abolished in TrpA1 null mice and the PLC inhibitor could also block TSLP-induced calcium increase in DRGs [79] . Thus, TSLP receptors are coupled to TrpA1 via PLC, similar to MrgprC11. Notably, TSLP-responsive DRG neurons are all TrpA1 and TrpV1 double positive, but do not respond to histamine or chloroquine. Therefore, TSLP marks a unique population of primary itch neurons. Interestingly, tryptase-evoked itch was also attenuated in both PAR2 and IL7α knockout mice. In addition, both tryptase and the PAR2 tethered ligand SLIGRL can trigger calcium-dependent TSLP release from keratinocytes. The ORAI1/NFAT calcium signaling pathway has also been identified as an essential regulator of TSLP release. These indicate that tryptase may cause itch via PAR2 mediated TSLP release from keratinocytes.
IL31 receptor
Interleukin 31 (IL31) is a cytokine preferentially produced from T helper type 2 cells. Levels of IL31 have been shown to increase in pruritic conditions such as atopic dermatitis and cutaneous T cell lymphoma [86, 87] . Like TSLP, mice with IL31 over-expression developed atopic dermatitis-like phenotypes. IL31 antibodies can also relieve itch and dermatitis symptoms in Nc/Nga mice which spontaneously develop dermatitis under conventional housing conditions [88, 89] . IL31 signals through the receptor complex of IL31 receptor A (IL31 RA) and oncostatin M receptor. IL31 RA expresses in about 4 % DRG neurons. These neurons respond to both capsaicin and mustard oil, representing a subset of MrgprA3 population. Consistent with previous findings, a recent study also reported elevated IL31 receptor expression in patients with atopic dermatitis and psoriasis. In an animal model of repeated allergen challenge-induced allergic dermatitis, IL31 level is also increased. Furthermore, both intradermal and intrathecal IL31 can directly produce itch in mice with ERK but not p38 phosphorylation downstream. Based on genetic deletion evidence, both TrpV1 and TrpA1 are required for IL31-induced itch response [90] . IL13, another Th2 cytokine mediating allergic diseases including asthma and dermatitis, has been reported to cause dermatitis with strong scratching when over expressed in mice. Interestingly, IL13 can upregulate TrpA1, while the TrpA1-specific antagonist attenuates IL13 over-expressionassociated itch [91] . Further studies are needed to elucidate the receptors and detailed signaling pathways involved in IL13 pruritogenesis.
Toll-like receptors and Trp channels
Toll-like receptors (TLRs) are a class of single-membrane spanning receptors playing key roles in innate immune systems. Immune cells such as macrophages and dendritic cells usually express toll-like receptors to detect microbe-derived molecules. Toll-like receptors function as dimers and may depend on co-receptors. Activated toll-like receptors recruit TIR domain containing adaptor proteins including MyD88, TRIF, TIRAP, and TRAM to trigger downstream responses such as release of cytokines and chemokines (Fig. 1b) [92] . TLR 3, 4, and 7 also express in dorsal root ganglia neurons [93] . Genetic deletions of TLR 3, 4, and 7 reduced itch responses toward multiple pruritogens. However, it remains unclear whether neuronal TLRs are required in itch transmission given the broad expression patterns of TLRs. Tissuespecific knockout lines of TLRs are needed to confirm the role of neuronal TLRs in itch.
Imiquimod (IQ), a small-molecule, anti-viral, anti-tumor immune modifier targeting TLR7, is used to treat genital warts which causes itch as a drug side effect [94, 95] . IQ directly activates TrpV1-expressing DRG neurons and induce itch independent of TrpV1 per se [96, 97] . However, the detailed mechanisms remain controversial. Liu et al. identified TLR7 as the mediator of IQ-induced itch. All four non-histamine pruritogens tested in the paper, including chloroquine (CQ), ET-1, and SLIGRL, exhibited significantly reduced scratching responses in TLR7 null mice, suggesting that TLR7 plays an essential role in non-histamine itch, instead of being a specific receptor of certain pruritogen. In contrast, Kim et al. reported unchanged IQ itch response in TLR7-deficient mice. Indeed, although IQ has been implicated in antagonizing adenosine receptors and potassium channels to increase neuronal excitability, the link between IQ and itch is still unclear [98, 99] . Interestingly, a recent paper by Park et al. reported that let 7b microRNA can directly activate DRG neurons and generate pain through TLR7. TrpA1 is a critical mediator in this TLR7 mediated pain, hinting at the potential role of TrpA1 in TLR7 itch responses [100] .
TLR3 and TLR4 are also implicated in itch transmission [101, 102] . The synthetic TLR3 agonist PIC can induce action potentials directly in TrpV1 expressing DRG neurons and elicits scratching behavior in a TLR3-dependent way. Strikingly, compound 48/80, CQ, ET-1, serotonin, SLIGRL, and trypsin-mediated itch were all greatly reduced in TLR3 knockout mice along with formalin second-phase pain and capsaicin-induced secondary hyperalgesia. This effect appears to involve central mechanisms since CQinduced calcium responses remained intact in TLR3 null mice, while spinal LTP was totally abolished. The downstream mechanism likely also involves TrpV1, as TrpV1 expression in DRG-central terminals, capsaicin-induced sEPSC increase in substantia gelatinosa neurons and intrathecal capsaicin-evoked licking behavior were all attenuated in TLR3 knockout [102] . TLR4 is also expressed in TrpV1-positive DRG neurons. Both histamine-and CQinduced itch were significantly reduced in TLR4 knockout. LPS, a TLR4 agonist can activate TrpV1 positive neurons and sensitize TrpV1 both in TLR4-dependent ways [103, 104] . However, LPS fails to generate scratching responses itself, leaving the role of direct LPS activation unknown. The reduced histamine response appears to involve TrpV1, as TrpV1 activity but not TrpA1 activity was decreased in TLR4 knockout. In contrast, the expression level of MrgprA3 was reduced in TLR4 deficient mice, likely responsible for the reduced CQ response [101] .
Pruritogens directly activate Trp channel
Oxidative stress contributes to the pathogenesis of multiple skin disorders, particularly those involving allergic reactions [105] . TrpA1 can be directly activated by a wide variety of irritants both exogenous and endogenous irritants, including oxidants [106] . Hydrogen peroxide and other oxidants can trigger calcium increase in DRG neurons and these responses are TrpA1-dependent [107] . Recent research shows that hydrogen peroxide and tert-butylhydroperoxide (tBHP) can induce dose-dependent scratching behaviors not affected by antihistamine. Both hydrogen peroxide and tBHP-induced itch can be reduced by either TrpA1 knockout or TrpA1 antagonist, revealing a novel itch mechanism where pruritogens directly target Trp channels (Fig. 1b) [108] . For a full list of pruritogens and related itch transmission mechanisms, please refer to Table 1 .
Trp channels and itch inhibition
By definition, itch can be inhibited by pain. Itch is an unpleasant sensation that elicits the desire to scratch thus generating moderate mechanical pain to inhibit itch. Two parallel reports point out there is tonic inhibition of itch pathways by pain even in the absence of pruritogen that deleting vGlut2, vesicular glutamate transporters in either TrpV1-positive or NaV1.8-positive nociceptors greatly reduced pain and not only boosted itch responses to multiple pruritogens, but also elicited spontaneous scratching [109, 110] .
Not just mechanical pain, but also other "counter stimuli," such as noxious heat and cooling can effectively block itch [111, 112] . TrpM8 is the Trp channel that responds to nonnoxious cooling temperature and compounds that produce cooling sensations, such as menthol and icilin. Agonists of thermal Trp channels such as TrpV1 agonist capsaicin, TrpA1 agonist mustard oil, and TrpM8 agonists menthol, icilin are able to inhibit itch [113, 114] , indicating involvement of thermal Trp channels. The inhibition of itch by pain can be directly observed in the spinal cord. By scratching the receptive field of histamine-responsive spinal projection neurons, the output of somatosensory information from the spinal cord can inhibit histamine-evoked activities, but not spontaneous or algogen-evoked activities [115] . The spontaneous activities of dorsal horn neurons in the chronic itch model are also inhibited by scratching, pinching, and noxious heat and this inhibition can be blocked by spinal GABA antagonists [116] , thus indicating involvement of a spinal inhibitory population.
A neural-specific transcription factor Bhlhb5 likely labels spinal interneurons which mediate itch inhibition. Deletion of Bhlhb5 resulted in loss of a population of inhibitory spinal interneurons (B5I for short) and spontaneous scratching [117] . The B5I population also expresses kappa opioid dynorphin and kappa opioid signaling potential contributes to the itch inhibition effect of this population consistent with previous finding that kappa opioid antagonists elicit strong scratching [118] . The B5I population receives direct synaptic inputs from TrpV1, TrpA1, and TrpM8-positive primary neurons transmitting counter-stimuli information from peripheral. Loss of Bhlhb5 interneurons abolished the inhibition effect of menthol on chloroquine-induced itch [119] confirming that counter-stimuli sensed by Trp channels work through Bhlhb5 inhibitory interneurons to achieve itch inhibition.
Trp channels in chronic itch
Trp channels play an essential role in chronic itch conditions in addition to their critical involvement in acute itch. Increased Trp channel expressions have been reported in multiple itchrelated diseases and critical involvement of Trp channels demonstrated in related animal studies. Therefore, Trp channels are receiving growing attention as potential drug targets for chronic itch diseases.
Increased Trp channel expression in chronic itch diseases
For example, TrpV1 is upregulated in multiple chronic itch conditions including neuronal and dermal over-expression in prurigo nodularis [120] , a skin disease characterized by itchy nodules on arms and legs, and in mast cells from mastocytosis [121] , an itchy skin condition caused by too many mast cells and precursors. TrpV1 is also upregulated in atopic dermatitis lesional skin [122] . TrpV1 activity increases in allergic rhinitis [123] , which features itchy eyes and sneezing. Notably, TrpV1 is increased in all four subtypes of rosacea, a chronic inflammation condition on central facial regions, while other TrpVs are also increased in certain subtypes despite their elusive link to itch [124] .
Another Trp channel with major role in itch transmission, TrpA1, is increased in nerve fibers, keratinocytes, and tryptase-positive mast cells from lesional skin of atopic dermatitis patients. Notably, dermal cells in healthy skin have minimal expression of TrpA1 [91] . In addition, expression of TrpV3 is also increased in atopic dermatitis lesional skin though its role in itch is not entirely clear [125] . Elevated TrpA1 expression is also detected in post-burn pruritus. Levels of TrpA1 and two other channels, TrpV3 and TrpV4, are all higher in post-burn patients with pruritus comparing with post-burn patients without pruritus [126] .
Unlike TrpV1 and TrpA1, TrpV3 expression is mainly detected in keratinocytes [127] . TrpV3 is a heat-activated Trp channel with a threshold around 33°C. Consistent with its expression in skin, TrpV3 plays an important role in skin physiology and pathophysiology. TrpV3 is a key regulator of skin barrier formation [128] . Activation of TrpV3 can trigger release of multiple factors including PGE2 [129] , ATP [130] , nitric oxide [131] , and NGF [132] , contributing to the inflammation processes in dermatitis. TrpV3 Gly573 mutations are detected in DS-Nh mice (Gly573Ser) and WBN/ Kob-Ht rats (Gly573Cys), both spontaneous hairless mutant strains. These animals develop spontaneous dermatitis phenotypes including increased keratinocytes and pruritus [133] . Transgenic mice carrying Gly573Ser mutation mimics dermatitis phenotypes from the two spontaneous mutant rodent strains confirming the causal role of this single amino acid mutation [132] . Recent studies also link this TrpV3 missense mutation to Olmsted syndrome (OS), a rare congenital disorder featuring palmoplantar, periorificial keratoderma and severe itching [134, 135] . OS patients were identified to carry missense mutation in TrpV3 gene (in most cases, Gly573Ser or Gly573Cys). Like TrpV3, TrpV4 is also found in keratinocytes and sensitive to warm temperature in addition to osmolarity change [136] [137] [138] [139] . TrpV4 agonists can promote, while TrpV4 antagonists inhibit skin barrier recovery and intercellular junctions were impaired in TrpV4 knockout mice [128, 140] . However, the role of TrpV4 in itch remains obscure.
Multiple TrpC channels have been implicated in keratinocyte differentiations. siRNA knockdown of TrpC1/ TrpC4 prevents calcium induced keratinocyte differentiation [141] while TrpC6 activation promote differentiation and inhibit proliferation via increased cytoplasmic calcium [142] . All six TrpC channels are downregulated in psoriasis, consistent with the excessive keratinocyte proliferation and impaired differentiation phenotypes of psoriasis [143] . In contrast, TrpC1 increases in Darier's disease, an autosomal dominant disorder caused by loss of function mutation of sarco (endo) plasmic reticulum Ca2 ATPase isoform 2b (SERCA2b) [144] . SERCA can transport calcium from cytosol to sarco(endo) plasmic reticulum at the expense of ATP. Darier's disease is characterized by dark crusty patches on the skin with intense itch and keratinocytes from Darier's disease patients show enhanced proliferation potentially caused by TrpC1-mediated apoptosis resistance [145] .
Trp channels in chronic itch animal models
With the help of animal models, the functions of Trp channels in chronic itch conditions are now being more thoroughly investigated. In addition to DS-Nh mice and WBN/Kob-Ht rats mentioned earlier, Nc/Nga is another mouse strain that spontaneously develops dermatitis with aging, and it is commonly used as a model for atopic dermatitis studies. In Nc/ Nga mice, antagonism of TrpV1 attenuates itch symptoms induced by house dust mite allergens [122] . Further, dermatitis-related itch in Nc/Nga mice is also reduced by serine protease inhibitor, PAR2 antibody [74], IL31 antibody [88] , and NK1R blocker [146] , thus suggesting multiple potential targets for treatment of dermatitis.
In addition to spontaneous mutants and genetically engineered animals over-expressing genes of interest (for instance IL31 and TSLP as mentioned earlier), repeated challenge of allergen is another common way of inducing allergic dermatitis symptoms in mice. However in oxazolone, haptens and urushiol (poison ivy allergen) challenged dermatitis models, genetic ablation or pharmacological blockade of TrpA1, but not TrpV1 effectively relieved scratching [147] . NK1R antagonists were also able to block this anti-histamine-resistant itch. Consistently, TrpA1 and HTR7 knockout mice both showed impaired scratching and dermatitis phenotypes in the model of topical vitamin D analog MC903-evoked atopic [46] . All the abovementioned evidence indicates a pivotal role of TrpA1 in chronic itch in addition to TrpV1. Although dermatitisrelated itch is widely regarded as anti-histamine-resistant, in the mouse model of contact dermatitis, L-histidine decarboxylase knockout (in which there is lost ability to produce histamine from histidine) completely abolished itch responses [121] . Consistently, H4R antagonism successfully reduced scratching with dermatitis model [148] . These results suggest the involvement of histamine in dermatitis and indicate the potential clinical value of H4R antagonists.
Dry skin (xerosis), skin dehydration with constant itch is another chronic itch condition commonly modeled in animals. Repeated skin dehydration with acetone and ether can trigger spontaneous scratching and increase trans-epidermal water loss without infiltration of inflammatory cells mimicking symptoms of xerosis [149, 150] . In animal model of dry skin, both TrpA1 and TrpV3 are required for induction of spontaneous itch [151] [152] [153] . Similar to dermatitis models, blocking serotonin signaling and PAR2 can also effectively reduce itch in dry skin models [154, 155] . Skin barriers play a critical role in preventing dehydration and entry of toxins, microbes and allergens. Damage of skin barrier integrity is thus commonly involved in both xerosis and dermatitis pathogenesis [156] . Trp channels are important regulators of skin barrier functions. In addition to TrpV3 and TrpV4 mentioned earlier, TrpA1 agonist also promotes skin barrier recovery [157] . In contrast, TrpV1 blocks skin barrier recovery as TrpV1 antagonist mimicked the effect of TrpA1 agonist [122] .
Trp channels and chronic itch treatments
Given the critical role of Trp channels in both chronic and acute itch, treatments targeting Trp channels are receiving more and more attention. Many clinical studies target TrpV1 for itch relief since it is the most studied Trp channel. TrpV1 antagonists have often been tested in clinical trials as analgesics, but side effects, such as hyperthermia due to disrupted body temperature regulation, have largely prevented their progression in clinical trials [158] . Recently, several TrpV1 antagonists have been tested for itch relief. PAC-14028, a TrpV1 antagonist effective in the mouse model of atopic dermatitis [122] , went through phase I clinical trial with low hyperthermia potential and good tolerability [159] . There are two finished phase II clinical trials with PAC-14028 targeting dermal pruritus and rosacea, respectively, though the results have yet to be published. Another TrpV1 antagonist SB-705498 was also tested as drug for itch-related diseases and was well tolerated in clinical trials. Intranasal SB-705498 was tested in phase II clinical trials targeting allergic rhinitis and nonallergic rhinitis, while topical SB-705498 was used to block histamine and cowhage induced itch in phase I trial. Intranasal SB-705498 attenuated capsaicin driven nasal hyper-reactivity in non-allergic rhinitis [160] , but had only limited effect in treating symptoms of allergic rhinitis symptoms [161] . Topical SB-705498, however, failed to demonstrate clinically relevant efficacy in relieving histamine or non-histamine itch [162] .
In addition to TrpV1 antagonists, topical TrpV1 agonists (for instance, capsaicin and resiniferatoxin) have also been considered as potential treatments for itch. Topical TrpV1 agonists have been used clinically for pain relief for many years, though the burning pain associated with this treatment hampers compliance [163] . Recently, topical TrpV1 agonists have shown efficacy in itch relief targeting multiple itch-related diseases including prurigo nodularis, psoriasis, uremic itch with hemodialysis, and idiopathic intractable itch despite occasional relapses after cessation of treatment [164] [165] [166] [167] . Although these studies cannot provide convincing evidence for the use of TrpV1 agonist in treating pruritus due to methodological issues such as improper blinding and crossover designs [168] , TrpV1 agonists demonstrate great potentials for clinical itch relief.
TrpA1 has received increasing attention in recent years as a potential drug target. A TrpA1 antagonist, GRC 17536, has finished phase II clinical trial and initial results are promising for treating diabetic neuropathy pain. As the major mediator for non-histamine itch, TrpA1 antagonists might have great potential for chronic itch conditions resistant to antihistamines. Cooling and compounds producing cooling sensation, as another counter-stimuli of itch, have also been considered as itch treatments. In placebo-controlled clinical research, the TrpM8 agonist, menthol, significantly reduced mustard gas exposure-induced itch in placebo-controlled clinical research [169] . There are also case reports confirming the role of menthol in reducing itch in conditions such as therapy-resistant pruritus in lichen amyloidosis [170] and hydroxyethyl starch-induced itch [171] . Another TrpM8 agonist icilin can also relieve vulva pruritus [113] .
Primary itch populations and Trp channels
Acute itch can be broadly categorized as histamine itch and non-histamine itch. The two forms are quite distinct from each other in many aspects in addition to their differential sensitivities to antihistamines. Histamine and non-histamine itch produced by cowhage, activate non-overlapping populations of projection neurons in the spinal cord [172] . Furthermore, activity-dependent silencing of the histamine-sensitive neurons with the lidocaine derivative QX-314 attenuates histamine but not chloroquine-induced scratching and vice versa [20] . However, the chloroquine sensitive primary neurons also respond to histamine, indicating an overlap of histamine and non-histamine primary itch populations. Moreover, ablation of MrgprA3 population affects not only chloroquine but also histamine and other pruritogen mediated itch [41] . A plausible explanation for the discrepancy is that chloroquine-responsive neurons are less sensitive to histamine than are the other histamine-responding neurons; thus, lower dose of histamine and non-histamine pruritogen can engage separable subsets of neurons. Indeed, high-dose histamine applied with QX-314 can attenuate chloroquine itch. Spinal projection neurons responsive to both histamine and cowhage, though small percentage, were also identified when larger numbers of neurons were included [173] .
Histamine itch is largely mediated by TrpV1-positive population as mentioned above, while non-histamine itch is usually mediated by TrpA1 and TrpV1 double positive neurons. MrgprA3 and C11 express in an overlapping population sensitive to both capsaicin and mustard oil. Bradykinin, IL31, and LTB4-induced itch require both TrpV1 and TrpA1, while most serotonin, TSLP, oxidant, and bile acid-sensitive neurons also respond to both capsaicin and mustard oil. IL31 population largely overlaps with MrgprA3 population [90] , while 5-HT7 receptor expression only partially with histamine and chloroquine receptors [46] . Consistently, MrgprA3 ablation only partially reduce serotonin mediated itch. In contrast, TSLP defines a unique population that seldom responds to histamine or chloroquine [79] . Likewise, MrgprD marks another separate population of itch neurons, which are not sensitive to histamine or chloroquine [42] .
A recent study by Usoskin et al. provides additional information regarding primary itch populations [174] . Single-cell RNA sequencings was done on 622 DRG neurons and the transcriptomes were used to categorize DRG neurons in an unbiased manner, independent of previous knowledge. Four neuronal clusters were identified. The non-peptidergic (NP) cluster was strongly linked to itch processing. The NP cluster was further divided into three subgroups NP1 to NP3 representing distinct itch populations. MrgprA3 was exclusively detected in the NP2 group and was expressed in over 60 % of NP2 group neurons. MrgprC11, as previously reported, mainly expressed in a slightly smaller NP2 population than did MrgprA3. However, a smaller subset of MrgprC11 positive cells was also found in the NP3 population.
The NP3 population harbors multiple itch receptors. Both IL31 receptor and OSMR were enriched in the NP3 population. 5HT1f receptor can serve as a good marker for the NP3 population as it is exclusively expressed in this population and covers 83 % of NP3 making it a good candidate of receptor of serotonin itch. Another highly expressing serotonin receptor 5HT2a was detected in both the NP3 and the PEP2 (from the peptidergic cluster) populations. Interestingly, cysteine leukotriene receptor 2 is highly expressed in the NP3 population. Cysteine leukotrienes are potent pro-inflammatory mediators that play an essential role in diseases such as allergic rhinitis, asthma, and atopic dermatitis. Cysteine leukotriene antagonists are effective in treating allergic rhinitis, atopic dermatitis, allergic urticaria, and other itch-related conditions in clinical studies [175] [176] [177] . However, the role of cysteine leukotrienes in pruritogenesis is unclear. The expression of cysteine leukotriene receptor 2 strongly suggests that the NP3 group may mediate pruritus induced by cysteine leukotrienes. Direct intradermal injection of LTD4 indeed elicited scratching confirming the sequencing result. Further experiments are needed to fully elucidate the pruritogenesis of cysteine leukotrienes. Another good marker for NP3 is natriuretic polypeptide b (nppb). nppb was exclusively found in NP3 and represents 83 % of the NP3 population. A recent report showed nppb knockout greatly attenuated itch mediated by all six pruritogens tested including histamine, chloroquine, serotonin, and SLIGRL [178] . Nppb is therefore proposed to be a neuropeptide required for itch perception in general and its expression in this versatile NP3 population largely matches this proposed role.
Histamine receptors, in contrast, were poorly detected. The H1R was only found at low level in the NP2 and the NP3 populations (and was only statistically significant in NP2). This could be caused by lower expression level of histamine receptors or limitation of detection methods. Nevertheless, histamine itch might be mediated by NP2 and NP3. Consistently, TrpV1 is strongly expressed in both NP2 and NP3 as well as in another peptidergic group PEP1. TrpA1, on the other hand, was highly detected in all three NP groups matching its pivotal role in itch. MrgprD, reported to label a unique itch population, can serve as a good marker for NP1 population as it covers 84 % of NP1 neurons. Another itchrelated receptor LPA3 receptor is also exclusively expressed in NP1 and covers 66 % of the NP1 population, thus making NP1 a good candidate mediating cholestatic itch. In addition to TrpA1, TrpC3 was also found in a high percentage of the NP1 cells making both of them good candidates mediating β-alanine and cholestatic itch.
Conclusions
With the rapid growth of our knowledge of the neuronal mechanisms of itch sensation in recent years, Trp channels downstream of receptors especially G protein-coupled receptors emerge as a common theme for itch signaling. Histamine itch and non-histamine itch are mainly mediated by TrpV1 and TrpA1, respectively. In addition, Trp channels can be coupled to cytokine receptors, toll-like receptors, or may even be directly activated by pruritogens. The diversity of itch transmissions, including receptors and downstream mediators not covered in this review, matches the diversity of exogenous and endogenous pruritogens and the complex etiology of itchy diseases involving not just neurons but dermal and immune cells as well. Trp channels also start to show greater and greater importance in chronic itch conditions. Further understandings of Trp channels in itch, particularly chronic itch, might provide invaluable knowledge for clinical itch treatments. 
